Lupin Launches Generic Rivaroxaban in the US

Lupin has introduced Rivaroxaban for Oral Suspension in the US market, offering a generic version of Xarelto. This medication treats venous thromboembolism (VTE) in children and provides thromboprophylaxis for those with congenital heart disease post-Fontan procedure. The product's annual US sales are about $11 million.

Devdiscourse News Desk | New Delhi | Updated: 01-10-2025 18:38 IST | Created: 01-10-2025 18:38 IST

Lupin Launches Generic Rivaroxaban in the US — This image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for illustrative purposes only.

Country:
India

Lupin, a major pharmaceutical company, announced the launch of Rivaroxaban for Oral Suspension in the United States. This generic medication is a version of Janssen Pharmaceuticals, Inc.'s Xarelto, designed to treat certain cardiovascular conditions in pediatric patients.

The suspension is primarily indicated for pediatric patients who have venous thromboembolism (VTE) and for reducing the risk of recurrent VTE. It is particularly beneficial for children aged two and older with congenital heart disease after the Fontan procedure, providing vital protection against thromboembolic events.

According to data from IQVIA MAT July 2025, the generic Rivaroxaban for Oral Suspension, at a concentration of 1 mg/mL, records estimated annual sales of $11 million in the US, reflecting its potential impact in the market.